Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

OTC Acetaminophen Label Guidance For Liver Warning Clarifies Ingredient Specifics

This article was originally published in The Tan Sheet

Executive Summary

FDA allows marketers of acetaminophen-containing OTC products to use an alternative liver warning, according to an updated guidance. The change from the draft, which aligns with a request by CHPA, separates maximum dosage for the ingredient from the dosage included in a certain product.

Advertisement

Related Content

In Most Consumers' OTC Pain Relief Decisions, Safety Missing As A Factor
Judge Rejects Prior Restraint For Tylenol Ads Ahead Of 'Bellwether' Trial
‘Double Check’ Acetaminophen Message Reaches Walmart Pharmacies
FDA Clarifies Label Warning For Acetaminophen Liver Damage
McNeil Lowers Recommended Maximum Dose For Extra Strength Tylenol

Topics

Advertisement
UsernamePublicRestriction

Register

PS108033

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel